// App-Quantinova.ai

Mo1208 : Timing of Influenza Vaccination Relative to Maintenance Infliximab Infusion in Inflammatory Bowel Disease Patients Does Not Impact Immune Response or Safety of Vaccine

Researchers

Presenter

  • Kevin Fonseca

Principal Investigators

  • Mariel Van Woudenberg

  • Subrata Ghosh

  • Miriam Fort Gasia

  • Aito Ueno

  • Remo Panaccione

  • Gilaad Kaplan

  • Cynthia H. Seow

  • Iwona T. Wrobel

Medical Centers

  • Microbiology, Provincial Laboratory of Public Health, Calgary, AB, Canada

  • Internal Medicine, University of Calgary, Calgary, AB, Canada

  • University of Calgary, Calgary, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

  • Crohn's disease

  • Influenza

Biomarkers

  • Interferon-gamma

  • Interleukin 1

  • Interleukin 6

  • Interleukin-8

Drug/Treatment

  • Infliximab

  • Fluviral

  • Agriflu

  • IFN-lambda

Outcome

  • N/A

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved